Global Breast Cancer Liquid Biopsy Market is expected to grow at a CAGR of 25.37% during the forecast period from 2018-2025
A new research report published by Fior Markets with the title Global Breast Cancer Liquid Biopsy Market by Circulating Biomarkers (Circulating Tumor Cells, Cell-free DNA, others), End User, Region and Global Forecast 2018-2025.
As per the report, the global breast cancer liquid biopsy market is expected to grow from USD 147.07 Million in 2017 to USD 879.41 Million by 2025 at a CAGR of 25.37% during the forecast period from 2018-2025. North America is dominating the market during the forecast period. Easy accessibility and high adoption of PCR and NGS among healthcare professionals and the increasing incidence of breast cancer are driving the demand in the region.
DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/376049/request-sample
Key players operating in the market include Bio-Rad Laboratories Inc., Janssen Diagnostics, Biocept Inc., Guardant Health, Inc., QIAGEN, Myriad Genetics, Roche AG, Trovagene Inc., Adaptive Biotechnologies, Epic Sciences, Cynvenio Biosystems, Inc., Illumina, Inc., Menarini Silicon Biosystems, MDxHealth, Sysmex Inostics GmbH, Genomic Health, NeoGenomics Laboratories, Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences, Inc, Isogen Life Science B.V. and others. Established and small players are actively focusing on research and development of methods in liquid biopsy through strategic partnerships. For instance, in May 2017, Natera collaborated with Baylor Genetics to develop a non-invasive prenatal test, Vistara. This test will help in detection of de novo mutations in single gene disorders. In addition, in November 2017, Biodesix, which is a U.S.-based company developed an innovative way of extracting circulating RNA from plasma in collaboration with Norgen Biotek.
Circulating biomarkers segment include circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The cfDNA segment is dominating the market and is expected to grow with the highest CAGR of 27.01% in the forecast period. Due to its occurrence in other body fluids along with the blood of cancer patients and the real-time results obtained by the analysis of cfDNA are the major factors contributing to the growth of cfDNA in the breast cancer liquid biopsy market. End user segment is divided into laboratories, hospitals and physician laboratories, and other end users. Reference laboratories segment held the largest market share and was valued around USD 60.27 million in 2017. Availability of advanced genetic testing equipment has increased volume of liquid biopsy test samples to reference laboratories
Rising prevalence of breast cancer cases around the world and increasing demand for better minimally invasive therapies for treatment are positively impacting the market. In addition, technological advancements to detect cancer at early stage are some of the factors contributing to the growth in forecast period. High cost of the treatment may restrict the growth of the market. However, commercialization of these liquid biopsy products, assays and tests are projected to boost the growth of the market.
About the report:
The global Breast Cancer Liquid Biopsy market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on firstname.lastname@example.org or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
- CDN Newswire